Rib-X Pharmaceuticals Named a 2011 Fierce 15 Company by FierceBiotech

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, was named by FierceBiotech today as one of 2011’s Fierce 15, designating it as one of the most promising private biotechnology companies in the industry.

“Rib-X is one of the most prominent in a group of biotech companies tackling a new generation of antibiotics,” says John Carroll, editor-in-chief of FierceBiotech. “Now teamed with Sanofi, it’s set out to prove that it has the technological know-how to produce a stream of reliable new bug-fighters. And next year it plans to launch a Phase III study, with IIb data scheduled to arrive by the end of the year.”

"We are gratified to receive this recognition from FierceBiotech on the heels of our recent deal with Sanofi and ahead of what promises to be an exciting ICAAC meeting where our RX-04 program will be showcased in 14 posters," said Mark Leuchtenberger, Rib-X’s President and Chief Executive Officer. "At Rib-X we are taking the public health crisis of antibiotic resistance head-on with the development of a fully-integrated, complementary pipeline of next generation compounds and novel classes of antibiotics to combat drug resistance and to address the broadest scope of antibacterial infection."

An internationally recognized daily newsletter reaching more than 90,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick, authoritative briefing on the day's top stories. Every year FierceBiotech evaluates hundreds of private companies for its annual list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

Now in its ninth year, the Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. A complete list of “Fierce 15” companies—the online newsletter’s ninth annual selection--is available online at www.fiercebiotech.com.

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 90,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Sign up is free at http://www.fiercebiotech.com.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals is developing broad spectrum antibiotics with superior coverage, safety and convenience to deliver new standards of care for patients with serious infections. The Company’s Nobel Prize winning platform enables a unique understanding of how antibiotics combat infection and has generated an industry leading pipeline spanning all phases of research and clinical development. www.rib-x.com



CONTACT:

Rib-X Pharmaceuticals, Inc.
Company
Jarrod Longcor, 203-848-3345
[email protected]
or
Investor Relations
Sarah Cavanaugh, 781-235-3060
[email protected]
or
Media Relations
Kari Watson, 781-235-3060
[email protected]

KEYWORDS:   United States  North America  Connecticut

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Infectious Diseases  Pharmaceutical  Research  Other Science  Science

MEDIA:

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.